Personalized Medicine in Rheumatology
Combination therapy with corticosteroids ups infection risk by almost 5-fold
By Neil Canavan
Berlin, Germany—Taking another step forward toward the realization of personalized medicine in rheumatology, German researchers presented the results of a new study that validated their original RABBIT (Rheumatoide Arthritis: Beobachtung der Biologika-Therapie) biologic register for rheumatoid arthritis (RA) risk score.
By Sy Schlager, MD, PhD
The effective use of biologic disease-modifying antirheumatic drugs (DMARDs) has dramatically improved the treatment of rheumatoid arthritis (RA) over recent years.
By Sy Schlager, MD, PhD
Belimumab (Benlysta) has recently been approved in the United States for the treatment of systemic lupus erythematosus (SLE), with a specific indication for use in adult patients with active, autoantibody-positive disease who are currently receiving standard therapies. However, the optimal use of this agent in SLE has not been well defined.